1. I do not agree with the author's notion that trials have been unsuccessful in mitigating hematoma expansion. It has been a relative constant observations in trials aiming at improving functional outcome in patients with intracerebral haemorrhage by targeting hematoma expansion, that hematoma expansion could be mitigated (at least with some success), but functional outcome was not improved (Sprigg et al, Lancet 2018; Mayer et al, NEJM 2008; Steiner et al, Lancet Neurol 2016; Qureshi et al, NEJM 2016 (trending) ) 2. I suggest, including as an objective whether the predictionscores were externally validated. 3. How do you intend to compare discrimination and calibration of the identified scores? Will you compare the discrimination and calibration obtained in the derivation cohorts or in validation cohorts? It might be more appropriate to compare the performance of the models demonstrated in validation cohorts. 4. It is mentioned, that the authors intend to screen abstracts accepted at major stroke conferences within the last 5-10 years. I find that "5-10" is to unspecific in the context of a systematic review. I suggest that the authors commit themselves to a predefined period. 5. I find the notion "Analysis of extracted data will be performed where appropriate and the exact analysis technique will be dictated on the types of data extracted" to unspecific. 
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GENERAL COMMENTS
The authors provide a protocol for planned scoping review to evaluate capabilities of hematoma expansion scores. The topic of the review is of relevance for the field, as optimized early prognostication of hematoma expansion in ICH patients may improve patient selection for future clinical ICH trials. The methodology to address the question is adequately selected (scoping review). Currently, there is no other scoping review on this specific topic registered with PROSPERO (checked July 09 2018). The authors state the criteria that they intend to use to include studies in their review, and they comment comprehensively on search strategies, data management, and data synthesis. The PCC concept (Population, Concept, Context) is adressed. The references include relevant the literature (methodology, research field). The manuscript is well written and adheres to recommendation for review protocols.
VERSION 1 -AUTHOR RESPONSE Reviewers' Comments to Author:
Reviewer: 1 This is a fair point. While we lack definitive treatments, overall care for intracerebral hemorrhage has improved significantly. The utilization of treatments like blood pressure reduction has been increasingly implemented in the last 10 years and may ultimately have an affect on hemorrhage volume. As such, scores developed in different time periods (1990s vs. 2010s) may have to be evaluated separately due to heterogoney in treatment quality. A cursory assessment indicates that the majority of scores to be included in this analysis were developed in the 2010s.
To further assess for heterogoney, populations used to develop/validate each score will be compared to each other. If significant heterogony exists, the score may have to be assessed separately. We have added these various elements into our methods section.
2-Will the authors include any study regardless of its size?
One concern is that studies involving only few patients or those which were only presented as abstracts but never published may not have the same rigor as larger/published studies?
We expect a paucity of fully published studies in our screening so we decided to open our analysis to include abstract data. While this may increase the risk of potential bias due to lessor analysis rigor in abstract data, the inclusion of these studies may increase our ability better evaluate the diagnostic capabilities of each score. In terms of study size, the reviewer makes an excellent point and it may be prudent to only include studies with an adequate number of patients for effective analysis. However, it is difficult to select an arbitrary threshold for a sample size. Therefore, we propose to do a sensitivity analysis with abstracts excluded.
3-The authors should provide some details regarding their data analysis plan & statistical methods.
Because our protocol is for that of a scoping review, we kept our data analysis plan and statistical methods deliberately broad as to create flexibility in our analysis options once we have screened and extracted data. In effect, one of the goals of this scoping review is to better understand the landscape of score development and assess whether there is enough data in the literature to warrant a proper meta-analysis.
With that being said, we have revised our protocol and will present a preliminary analysis plan in the manuscript. To summarize, if the data extracted allows for it, we will compare the diagnostic summary makers of each score to each other in a pair-wise manner. Because each score is presented on a continuous scale (i.e. HEP 0-18, BRAIN 0-24, BAT 0-6 ) and because each score may present data with different positivity thresholds, we will make overall comparisons of the scores using summary ROC curves (an estimation of the expected ROC curve for a test across many thresholds). 
